Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral gpASIT+TM for prophylaxis of seasonal grass pollen rhinoconjunctivitis
2010-023176-12Phase 2Completed
- Sponsor
- TOOLS Life Science
- Start
- Oct 2010
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gpASIT+ in seasonal allergic rhinitis (SAR) and allergic rhinitis (AR) (3 arms), sponsored by TOOLS Life Science. Primary endpoint: Primary rhinoconjunctivitis efficacy endpoint. Started Oct 2010; status: completed.
02
Drugs
gpASIT+
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2010-023176-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023176-12.